Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver disease.
Keene
Adam
A
Kawano
Thomas
T
Anees
Syed
S
Chen
Julie
J
D018806:APACHE; D000925:Anticoagulants / Q000009:adverse effects*; D000075202:Contraindications; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008107:Liver Diseases / Q000145:classification / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects*; D012189:Retrospective Studies; D012306:Risk
D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins